151
|
Lim T, Yun J, Lee J, Park S, Park J, Park Y, Lim H, Kang W. Updated survival results of the randomized phase II study comparing cisplatin/capecitabine (CX) with epirubicin plus CX (ECX) in advanced gastric cancer (AGC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.46] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
46 Background: We previously reported results of a randomized study showing that CX is equally active to ECX in terms of progression-free survival (PFS) (Yun et al. Eur J Cancer. 2010). Here we report updated overall survival (OS) results with an additional 12 months' follow-up. Methods: Ninety-one chemotherapy-naïve patients with histologically-confirmed, measurable AGC were randomized to receive CX (cisplatin 75 mg/m2 iv on day 1 and capecitabine 1,000 mg/m2 bid po on days 1-14, n=45) or ECX (epirubicin 50 mg/m2 plus CX, n=44) every 3 weeks. After CX or ECX had failed, second-line chemotherapy (SLC) was recommended for all patients if their performance status was preserved. Results: Treatment duration was similar for both arms (4.4 for CX v 4.2 months for ECX). There was no relevant difference in the occurrence of overall grade 3 or 4 toxicities between the CX and ECX arms (80% v 78%, respectively; p=0.516). However, none in the CX and 12% in the ECX arm discontinued treatment because of toxicity. There were no significant differences in therapeutic efficacy between CX and ECX with respect to the response rate (38% v 37%, respectively), PFS (6.4 v 6.5 months), as well as OS (12.7 v 13.8 months; p=0.51). After failure, 60% of patients (26 CX and 28 ECX patients) received SLC. However, OS was not differed whether a patient was treated with SLC or not (13.1 v 11.2 months; p=0.94). Conclusions: The present analysis confirms previous findings that both CX and ECX appear to be comparatively active as first-line chemotherapy for AGC. Furthermore, the role of SLC in AGC warrants further evaluation. No significant financial relationships to disclose.
Collapse
|
152
|
Lim H, Utyuzhnikov SV, Lam YW, Turan A. Multi-domain active sound control and noise shielding. THE JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA 2011; 129:717-725. [PMID: 21361431 DOI: 10.1121/1.3531933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
This paper describes an active sound control methodology based on difference potentials. The main feature of this methodology is its ability to automatically preserve "wanted" sound within a domain while cancelling "unwanted" noise from outside the domain. This method of preservation of the wanted sounds by active shielding control is demonstrated with various broadband and realistic sound sources such as human voice and music in multiple domains in a one-dimensional enclosure. Unlike many other conventional active control methods, the proposed approach does not require the explicit characterization of the wanted sound to be preserved. The controls are designed based on the measurements of the total field on the boundaries of the shielded domain only, which is allowed to be multiply connected. The method is tested in a variety of experimental cases. The typical attenuation of the unwanted noise is found to be about 20 dB over a large area of the shielded domain and the original wanted sound field is preserved with errors of around 1 dB and below through a broad frequency range up to 1 kHz.
Collapse
|
153
|
Cunningham D, Park S, Kang Y, Chao Y, Chen L, Rees C, Lim H, Tabernero J, Yeh G, De Gramont A. Randomized phase II study of PEP02, irinotecan, or docetaxel as a second-line therapy in gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6 Background: PEP02 is a novel nanoparticle liposome formulation of irinotecan (CPT-11). In phase I studies, PEP02 has improved pharmacokinetics (PK) of CPT-11 and its active metabolite-SN38 with encouraging safety and tumor response in several cancer types including gastric cancer. This study evaluated the efficacy and safety of PEP02 (P), irinotecan (I) or docetaxel (D) as a single agent in gastric or gastroesophageal junction (GEJ) adenocarcinoma. Methods: A randomized, 3 arms (1:1:1), Simon's 2-stage (2/21, 5/41 based on tumor response) study was conducted in Europe and Asia. Patients (pts) with locally advanced or metastatic disease, failed to one prior chemotherapy, ECOG PS ≤ 2, at least 1 measurable lesion, no prior CPT-11 or taxane, were treated with P - 120 mg/m2, I - 300 mg/m2, or D - 75 mg/m2 every 3 weeks. PK and pharmacogenetics (PGx) samples were collected for pts in P and I arms. Results: A total of 135 pts were randomized with 132 (44 per arm) treated between Jan 2008 and Jun 2010. Pts demographics (P/I/D): median age: 56/62/58, male (%): 79.5/77.3/77.3, Pts from Europe (%): 54.6/52.3/56.8, metastatic (%): 97.7/90.9/97.7, gastric adenocarcinoma (%): 84.1/79.6/68.2, and ECOG 0 + 1 (%): 93.2/93.2/90.9. The confirmed responders of P/I/D were 6 (13.6%)/3 (6.8%)/7 (15.9%) and disease control were 27 (61.4%)/27 (61.4%)/24 (54.6%). These three arms have similar progression free survival and overall survival. If stratified by region, Asian pts had longer survival than European pts. Toxicities of P/I/D were: grade 3/4 neutropenia (%): 9.1/13.6/15.9. grade 3/4 diarrhea (%): 27.3/18.2/2.3, hand-foot syndromes (%): 0.0/6.8/18.2. It was notable that symptoms related to acute cholinergic syndrome were less reported in P arm than in I arm. The PK data showed the mean T1/2, Cmax and AUC0→∞ of SN-38 in P/I arms were 88.8/22.8 hr, 8.79/44.1 ng/mL and 879/440 hr x ng/mL. Conclusions: This randomized phase II study suggests that PEP02 improves the PK profile and tumor response over irinotecan, and it is as efficacious as docetaxel in the 2nd-line treatment for gastric or GEJ adenocarcinoma. PEP02 is worthy of further evaluation as either 1st- or 2nd-line setting in future gastric cancer studies. [Table: see text]
Collapse
|
154
|
Lee S, Park J, Park S, Kang W, Lim H, Park Y, Park K, Lee J. A retrospective study of first-line combination chemotherapy in advanced colorectal cancer: A Korean single-center experience. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
623 Background: Fluoropyrimidine-based combination chemotherapy, in combination with either oxaliplatin or irinotecan, have demonstrated efficacy and tolerability against advanced colorectal cancer (ACC). Methods: Between Jan 2006 and Dec 2007, 478 ACC patients were treated with combination chemotherapy in first-line setting: 5-fluorouracil, folinic acid plus oxaliplatin (FOLFOX, n=172), 5-fluorouracil, folinic acid plus irinotecan (FOLFIRI, n=95), capecitabine plus oxaliplatin (XELOX, n=155), and capecitabine plus irinotecan (XELIRI, n=56). FOLFOX and FOLFIRI were repeated every 2 weeks, whereas XELOX and XELIRI were repeated every 3 weeks until disease progression or unacceptable toxicity occurred or until a patient chose to discontinue treatment. Results: The median age was 58 years (range, 19-84 years) and the median chemotherapy duration for FOLFOX, FOLFIRI, XELOX and XELIRI were 4.9, 4.5, 5.7 and 5.4 months, respectively. Combination chemotherapy regimens were generally well tolerated. The estimated median PFS for all patients was 6.8 months (95% confidence interval, 6.3-7.3 months). No statistically significant difference in PFS was found each regimen used as first-line chemotherapy. Sixty-percent (n=290) of patients received second or further lines of therapy after failure. Conclusions: Fluoropyrimidine-based combination chemotherapy regimens appear to be equally active and tolerable as first-line therapy for ACC. No significant financial relationships to disclose.
Collapse
|
155
|
Baek K, Kim J, Um J, Park S, Lee J, Park J, Park Y, Lim H, Kang W. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: A comparison with previously known prognostic models. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
323 Background: Sorafenib, a multiple-targeted tyrosine kinase inhibitor, is now the treatment of choice for systemic therapy of patients with advanced hepatocellular carcinoma (HCC). Herein we present the clinical characteristics and outcomes of patients with advanced HCC who were treated with sorafenib. Methods: Data of 201 sorafenib-treated, metastatic HCC patients were collected from a single institution tumor registry. The primary and secondary endpoints were overall survival (OS) and failure-free survival (FFS). Results: Chronic hepatitis B was the predominant cause of HCC (84%).Of 162 evaluable patients, four partial responses were recorded. With a median follow-up of 15.7 months, the median FFS and OS were 2.5 months (95% confidence interval [CI], 2.3-2.7 months) and 5.3 months (95% CI, 4.4-6.3 months), respectively. In multivariate analysis, the prognostic factors associated with FFS were the presence of ascites, portal venous thrombosis, serum alpha- fetoprotein (AFP) ≥400 ng/mL, albumin, bilirubin, tumor size and number, and performance status. Likewise, the presence of ascites, portal venous thrombosis, tumor size and number, performance status, and baseline levels of AFP, albumin and bilirubin were significantly related with OS. After adjusting for performance status, the Cancer of the Liver Italian Program (CLIP) scoring system and Okuda stages can better predict the hazard of failure or death than Child-Pugh classification. Conclusions: Our results suggest that CLIP scores or Okuda stages, along with performance status, can be useful in stratifying patients with advanced HCC treated with sorafenib. No significant financial relationships to disclose.
Collapse
|
156
|
Lee D, Lee J, Lim D, Kim S, Park S, Park J, Park Y, Lim H, Kang W. A phase I study of neoadjuvant chemoradiotherapy with S-1/oxaliplatin in patients with gastric cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.51] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
51 Background: To determine the maximum tolerated dose (MTD) of concurrent radiotherapy with S-1 and oxaliplatin, and antitumor activity of the combination treatment in patients with gastric cancer. Methods: This was a phase I, escalating multiple-dose tolerability trial. S-1 and oxaliplatin were administered concurrently with radiotherapy for 4 weeks before surgery. The dose escalation scheme is provided in the table below. S-1 was continuously administered during radiotherapy and oxaliplatin was administered weekly for 4 weeks during radiotherapy. Results: From March 2009 to June 2010, twelve patients were entered at two dose levels. The most common dose-related grade 1 and 2 adverse events were nausea, vomiting, anorexia and abdominal pain. Two of six patients treated at level 1 developed DLT (disabling abdominal pain, stomach perforation). The dose of S-1/oxaliplatin was reduced to 30 mg/m2 bid and 40 mg/m2 (Level -1). There one DLT (vomiting and anorexia, grade 3) observed in the expanded cohort of 6 patients at Level -1. Among 12 patients, 1 patient demonstrated pathological CR after neoadjuvant chemoradiation therapy. Conclusions: Neoadjuvant CCRT with S-1/oxaliplatin was well tolerated, at a dose 30 mg/m2 bid for S-1 and 40 mg/m2 for oxaliplatin that at which antitumor activity was seen. Phase II study is planned to investigate further the efficacy, tolerability and optimal dose. [Table: see text] No significant financial relationships to disclose.
Collapse
|
157
|
Thongprasert S, Qin S, Lim H, Bhudhisawasdi V, Yin X, Gang W, Kim B, Jian Z, Yang T, Rau K. Efficacy of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin in advanced HCC: Updates on the EACH study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
160 Background: In Asia, where hepatitis B is very common, patients often present with locally advanced or metastatic hepatocellular carcinoma (HCC), and their prognosis is poor. The EACH study was designed to evaluate the efficacy and safety of FOLFOX4 vs. doxorubicin as palliative systemic chemotherapy in advanced HCC. Methods: The open-label, randomized, multicenter phase III study was conducted in 371 patients in China, Taiwan, Korea and Thailand, who had locally advanced or metastatic HCC and were ineligible for resection. Patients were randomized 1:1 to receive either FOLFOX4 (oxaliplatin 85 mg/m2 i.v. d1; LV 200 mg/m2 i.v. h0–h2 d1 and d2; 5FU 400 mg/m2 i.v. bolus h2, then 600 mg/m2 over 22 hours d1 and d2 q2w) or doxorubicin (50 mg/m2 i.v. q3w). The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), response rate (RR) by RECIST and safety. Data from final and follow-up analyses of the intent-to-treat (ITT) population and selected subgroup analyses are presented. Results: At the final analysis, median OS with FOLFOX4 (N = 184) was 6.40 months (95% CI: 5.30, 7.03) vs. 4.97 months (95% CI: 4.23, 6.03) with doxorubicin [N = 187; p = 0.0695 using a stratified log-rank test; statistical significance (p = 0.0425) was achieved at the post hoc follow-up analysis conducted 7 months later]. Median PFS with FOLFOX4 was 2.93 months (95% CI: 2.43, 3.53) vs. 1.77 months with doxorubicin (95% CI: 1.63, 2.30; p = 0.0002). The RR was 8.2% vs. 2.7% of patients with FOLFOX4 and doxorubicin, respectively (p = 0.0233), and the disease control rate (DCR) was 52.2% vs. 31.6% (p < 0.0001). In the Chinese sub-population, OS, PFS, RR and DCR were significantly improved with FOLFOX4 vs. doxorubicin at both the final and follow-up analyses. In the other subgroups analyzed, the OS and PFS benefits of FOLFOX4 vs. doxorubicin were generally consistent. Conclusions: In the ITT population, median OS was greater with FOLFOX4 than doxorubicin throughout the study and statistical significance was achieved after continued follow-up. FOLFOX4 can benefit patients with advanced HCC, as it significantly increases median OS, PFS, RR and DCR compared with doxorubicin. [Table: see text]
Collapse
|
158
|
Schultz C, Willoughby S, Lim H, John B, Chandy S, Lau D, Roberts-Thomson K, Young G, Sanders P. Transseptal Puncture and Thrombotic Risk. Heart Lung Circ 2011. [DOI: 10.1016/j.hlc.2011.05.275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
159
|
Lim H, Willoughby S, Schultz C, Gan C, Brooks A, Alasady M, Lau D, Roberts-Thomson K, Worthley M, Young G, Sanders P. Effect of Atrial Fibrillation and Increased Atrial Rates on Markers of Left Atrial Thrombogenesis in Humans. Heart Lung Circ 2011. [DOI: 10.1016/j.hlc.2011.05.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
160
|
Willoughby S, Lau D, Schultz C, Lim H, Mahajan R, Nayyar S, Worthley M, Sanders P. Correlation Between Radial Artery- and Peripheral Arterial Tonometry Derived Augmentation Index in Patients with Atrial Fibrillation. Heart Lung Circ 2011. [DOI: 10.1016/j.hlc.2011.05.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
161
|
Schultz C, Willoughby S, Lim H, John B, Chandy S, Lau D, Roberts-Thomson K, Young G, Sanders P. Is Rapid Atrial Pacing Associated with Thrombogenesis in Normal Hearts? Heart Lung Circ 2011. [DOI: 10.1016/j.hlc.2011.05.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
162
|
Alasady M, Brooks A, Proctor S, Chia N, Barlow D, Lim H, Abhayaratna W, Sanders P. Impact of Coronary Artery Disease Intervention on the Incidence and Prognosis of Atrial Fibrillation after Acute Myocardial infarction: A Systematic Review. Heart Lung Circ 2011. [DOI: 10.1016/j.hlc.2011.05.238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
163
|
Willoughby S, Lim H, Wong C, Schultz C, Roberts-Thomson K, Young G, Sanders P. Effect of Electrical Cardioversion of Atrial Fibrillation on Endothelial Function and Haemostasis. Heart Lung Circ 2011. [DOI: 10.1016/j.hlc.2011.05.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
164
|
Chung SP, Cho J, Park YS, Kang HG, Kim CW, Song KJ, Lim H, Cho GC. Effects of script-based role play in cardiopulmonary resuscitation team training. Emerg Med J 2010; 28:690-4. [DOI: 10.1136/emj.2009.090605] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
165
|
Baerwald A, Rouleau D, Bhatt H, Lim H, Gamelin A, Case A. Serial ultrasonographic evaluation of individually-identified follicles in women during ovarian stimulation. Fertil Steril 2010. [DOI: 10.1016/j.fertnstert.2010.07.824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
166
|
Kang Y, Ohtsu A, Van Cutsem E, Rha SY, Sawaki A, Park S, Lim H, Wu J, Langer B, Shah MA. AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.18_suppl.lba4007] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA4007 Background: The median survival for patients (pts) with AGC in most phase III studies is less than 1 year. The addition of bevacizumab (bev) to chemotherapy (chemo) is supported by a strong preclinical rationale and by phase II evaluation. AVAGAST is the first randomized study to compare the efficacy and safety of bev + chemo vs placebo + chemo. Methods: Pts with inoperable, locally advanced or metastatic stomach/gastroesophageal junction adenocarcinoma with no prior therapy were randomized 1:1 to capecitabine (cape, or 5-FU) + cisplatin (cis) and either bev (7.5 mg/kg iv) or placebo q3w. Stratification variables: geographical region, fluoropyrimidine treatment, disease status. Cis was given for 6 cycles; bev/placebo + cape/5-FU were given until disease progression or unmanageable toxicity. Primary objective: compare overall survival (OS); secondary objectives: compare progression-free survival (PFS), overall response rate (ORR), and safety (as overseen by an independent DSMB). Results: From Sep 2007 to Dec 2008, 774 pts were enrolled. Treatment arms were balanced. Approx 95% of pts were metastatic. Two-thirds of pts were male, 49% of pts were from Asia/Pacific, 32% from Europe and 19% from the Americas. Median OS was 10.1 months with chemo + placebo and 12.1 months with chemo + bev in the intent-to-treat population (HR 0.87; p=0.1002). Median OS according to geographical region was 6.8 vs. 11.5 months (HR 0.63) in the Americas, 8.6 vs. 11.1 months (HR 0.85) in Europe and 12.1 vs. 13.9 months in Asia-Pacific (HR 0.97). Secondary endpoints and AEs of special interest for Bev are summarized below ( Table ). Conclusions: While the primary endpoint was not met (median OS HR 0.87; p=0.1002), there was a significant improvement in PFS and ORR and an acceptable safety profile for bev + chemo in patients with AGC. [Table: see text] [Table: see text]
Collapse
|
167
|
Holden JF, Poole Ii FL, Tollaksen SL, Giometti CS, Lim H, Yates Iii JR, Adams MW. Identification of membrane proteins in the hyperthermophilic archaeon pyrococcus furiosus using proteomics and prediction programs. Comp Funct Genomics 2010; 2:275-88. [PMID: 18629240 PMCID: PMC2448401 DOI: 10.1002/cfg.110] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2001] [Accepted: 08/20/2001] [Indexed: 11/10/2022] Open
Abstract
Cell-free extracts from the hyperthermophilic archaeon Pyrococcus furiosus were
separated into membrane and cytoplasmic fractions and each was analyzed by 2D-gel
electrophoresis. A total of 66 proteins were identified, 32 in the membrane fraction and 34
in the cytoplasmic fraction. Six prediction programs were used to predict the subcellular
locations of these proteins. Three were based on signal-peptides (SignalP, TargetP, and
SOSUISignal) and three on transmembrane-spanning α-helices (TSEG, SOSUI, and
PRED-TMR2). A consensus of the six programs predicted that 23 of the 32 proteins
(72%) from the membrane fraction should be in the membrane and that all of the proteins
from the cytoplasmic fraction should be in the cytoplasm. Two membrane-associated
proteins predicted to be cytoplasmic by the programs are also predicted to consist
primarily of transmembrane-spanning β-sheets using porin protein models, suggesting that
they are, in fact, membrane components. An ATPase subunit homolog found in the
membrane fraction, although predicted to be cytoplasmic, is most likely complexed with
other ATPase subunits in the membrane fraction. An additional three proteins predicted to
be cytoplasmic but found in the membrane fraction, may be cytoplasmic contaminants.
These include a chaperone homolog that may have attached to denatured membrane
proteins during cell fractionation. Omitting these three proteins would boost the
membrane-protein predictability of the models to near 80%. A consensus prediction using
all six programs for all 2242 ORFs in the P. furiosus genome estimates that 24% of the
ORF products are found in the membrane. However, this is likely to be a minimum value
due to the programs’ inability to recognize certain membrane-related proteins, such as
subunits associated with membrane complexes and porin-type proteins.
Collapse
|
168
|
Qin S, Bai Y, Ye S, Fan J, Lim H, Cho JY, Thongprasert S, Chao Y, Rau K, Sun Y. Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4008] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
169
|
Yi J, Ahn H, Lee S, Uhm J, Lee J, Park S, Park J, Park Y, Lim H, Kang W. A phase I clinical trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
170
|
Lee S, Won H, Son E, Lee J, Park S, Park J, Park Y, Lim H, Kang W. Genetic polymorphism associated with chronic neurotoxicity and recurrence in curatively-resected colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3583] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
171
|
Park S, Lee S, Kong J, Yun J, Kim J, Park J, Park Y, Lim H, Kang W. Prechemotherapy hemoglobin levels and survival in patients with advanced urothelial carcinoma who received a first-line gemcitabine/platinum(GP)-based regimen: Results of a single center retrospective study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e15123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
172
|
Lee J, Kim P, Liu X, Park J, Ng S, Lee T, Lim H, Singh S, Kim S, Kang W. Functional profiling of signal transduction pathway proteins in gastric cancer (GC) patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
173
|
Park S, Lee S, Kang J, Hwang I, Lee J, Park J, Park Y, Lim H, Kang W. A feasibility analysis from the patient preference randomized phase III clinical trial of second-line chemotherapy (SLC) in advanced gastric cancer (AGC) patients pretreated with both fluoropyrimidines and platinum. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
174
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Al-Jamel A, Aoki K, Aphecetche L, Armendariz R, Aronson SH, Asai J, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Baksay G, Baksay L, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Bathe S, Batsouli S, Baublis V, Bauer F, Bazilevsky A, Belikov S, Bennett R, Berdnikov Y, Bickley AA, Bjorndal MT, Boissevain JG, Borel H, Boyle K, Brooks ML, Brown DS, Bucher D, Buesching H, Bumazhnov V, Bunce G, Burward-Hoy JM, Butsyk S, Campbell S, Chai JS, Chang BS, Charvet JL, Chernichenko S, Chiba J, Chi CY, Chiu M, Choi IJ, Chujo T, Chung P, Churyn A, Cianciolo V, Cleven CR, Cobigo Y, Cole BA, Comets MP, Constantin P, Csanád M, Csörgo T, Dahms T, Das K, David G, Deaton MB, Dehmelt K, Delagrange H, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drachenberg JL, Drapier O, Drees A, Dubey AK, Durum A, Dzhordzhadze V, Efremenko YV, Egdemir J, Ellinghaus F, Emam WS, Enokizono A, En'yo H, Espagnon B, Esumi S, Eyser KO, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Forestier B, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fung SY, Fusayasu T, Gadrat S, Garishvili I, Gastineau F, Germain M, Glenn A, Gong H, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HA, Hachiya T, Hadj Henni A, Haegemann C, Haggerty JS, Hagiwara MN, Hamagaki H, Han R, Harada H, Hartouni EP, Haruna K, Harvey M, Haslum E, Hasuko K, Hayano R, Heffner M, Hemmick TK, Hester T, Heuser JM, He X, Hiejima H, Hill JC, Hobbs R, Hohlmann M, Holmes M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Hur MG, Ichihara T, Imai K, Inaba M, Inoue Y, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Jacak BV, Jia J, Jin J, Jinnouchi O, Johnson BM, Joo KS, Jouan D, Kajihara F, Kametani S, Kamihara N, Kamin J, Kaneta M, Kang JH, Kanou H, Kawagishi T, Kawall D, Kazantsev AV, Kelly S, Khanzadeev A, Kikuchi J, Kim DH, Kim DJ, Kim E, Kim YS, Kinney E, Kiss A, Kistenev E, Kiyomichi A, Klay J, Klein-Boesing C, Kochenda L, Kochetkov V, Komkov B, Konno M, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kroon PJ, Kubart J, Kunde GJ, Kurihara N, Kurita K, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Le Bornec Y, Leckey S, Lee DM, Lee MK, Lee T, Leitch MJ, Leite MAL, Lenzi B, Lim H, Liska T, Litvinenko A, Liu MX, Li X, Li XH, Love B, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mao Y, Masek L, Masui H, Matathias F, McCain MC, McCumber M, McGaughey PL, Miake Y, Mikes P, Miki K, Miller TE, Milov A, Mioduszewski S, Mishra GC, Mishra M, Mitchell JT, Mitrovski M, Morreale A, Morrison DP, Moss JM, Moukhanova TV, Mukhopadhyay D, Murata J, Nagamiya S, Nagata Y, Nagle JL, Naglis M, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Norman BE, Nyanin AS, Nystrand J, O'Brien E, Oda SX, Ogilvie CA, Ohnishi H, Ojha ID, Okada H, Okada K, Oka M, Omiwade OO, Oskarsson A, Otterlund I, Ouchida M, Ozawa K, Pak R, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park J, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Pisani RP, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reuter M, Reygers K, Riabov V, Riabov Y, Roche G, Romana A, Rosati M, Rosendahl SSE, Rosnet P, Rukoyatkin P, Rykov VL, Ryu SS, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakata H, Samsonov V, Sato HD, Sato S, Sawada S, Seele J, Seidl R, Semenov V, Seto R, Sharma D, Shea TK, Shein I, Shevel A, Shibata TA, Shigaki K, Shimomura M, Shohjoh T, Shoji K, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh CP, Singh V, Skutnik S, Slunecka M, Smith WC, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sullivan JP, Sziklai J, Tabaru T, Takagi S, Takagui EM, Taketani A, Tanaka KH, Tanaka Y, Tanida K, Tannenbaum MJ, Taranenko A, Tarján P, Thomas TL, Togawa M, Toia A, Tojo J, Tomásek L, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Tuli SK, Tydesjö H, Tyurin N, Vale C, Valle H, van Hecke HW, Velkovska J, Vertesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Wagner M, Walker D, Wang XR, Watanabe Y, Wessels J, White SN, Willis N, Winter D, Woody CL, Wysocki M, Xie W, Yamaguchi YL, Yanovich A, Yasin Z, Ying J, Yokkaichi S, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zhou S, Zimányi J, Zolin L. Enhanced production of direct photons in Au + Au collisions at square root(S(NN)) = 200 GeV and implications for the initial temperature. PHYSICAL REVIEW LETTERS 2010; 104:132301. [PMID: 20481877 DOI: 10.1103/physrevlett.104.132301] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/25/2008] [Revised: 12/02/2009] [Indexed: 05/29/2023]
Abstract
The production of e+ e- pairs for m(e+ e-)<0.3 GeV/c2 and 1<p(T)<5 GeV/c is measured in p+p and Au+Au collisions at square root(S(NN))=200 GeV. An enhanced yield above hadronic sources is observed. Treating the excess as photon internal conversions, the invariant yield of direct photons is deduced. In central Au+Au collisions, the excess of the direct photon yield over p+p is exponential in transverse momentum, with an inverse slope T=221+/-19(stat)+/-19(syst) MeV. Hydrodynamical models with initial temperatures ranging from T(init) approximately 300-600 MeV at times of approximately 0.6-0.15 fm/c after the collision are in qualitative agreement with the data. Lattice QCD predicts a phase transition to quark gluon plasma at approximately 170 MeV.
Collapse
|
175
|
Leong D, Ma J, Lau D, Alasady M, Wilson L, Kyriacou N, Lim H, Carlson S, McGavigan A, Sanders P. Ventricular Dependence of Left Atrial Mechanical Function. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
176
|
Lim H, Willoughby S, Schultz C, Lau D, Alasady M, Leong D, Brooks A, Dimitri H, Dang J, Sharma G, Hillock R, Roberts-Thomson K, Worthley M, Young G, Sanders P. Left Atrial Platelet Activation in Patients with Non-Valvular Atrial Fibrillation. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
177
|
Wilson L, Wong C, Kuklik P, Brooks A, Kyriacou N, Lau D, Alasady M, Lim H, Abed H, Young G, Sanders P. Left Atrial and Pulmonary Vein Dimensions are Dependent on ECG-Gating of Computed Tomography in Sinus Rhythm and Atrial Fibrillation. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
178
|
Wilson L, Wong C, Brooks A, Kyriacou N, Kuklik P, Lau D, Lim H, Alasady M, Abed H, Dimitri H, Young G, Sanders P. Incidence and Characteristics of Left Atrial Diverticula in Patients Undergoing AF Ablation. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
179
|
Lovell A, Choi B, Leong D, Alasady M, Lim H, Young G, Sanders P. The Effect of Heart Rate on Ventricular Mechanical Dyssynchrony. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
180
|
Schultz C, Willoughby S, Lim H, John B, Chandy S, Alasady M, Dimitri H, Lau D, Laborerie J, Roberts-Thomson K, Young G, Sanders P. Endothelial Dysfunction and Vascular Inflammation in Patients with Atrial Fibrillation. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
181
|
Cheng Y, Wong C, Brooks A, Lau D, Leong D, Shipp N, Alasady M, Lim H, Abed H, Worthley M, Worthley S, Sanders P. Trends Comparing Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in Australia: 2000–2008. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
182
|
Wong C, Cheng Y, Lau D, Leong D, Brooks A, Shipp N, Alasady M, Lim H, Abed H, Roberts-Thomson K, Sanders P. Atrial Fibrillation in Indigenous Aboriginal Australians. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.624] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
183
|
Wong C, Cheng Y, Leong D, Lau D, Brooks A, Abed H, Lim H, Alasady M, Shipp N, Roberts-Thomson K, Sanders P. Atrial Fibrillation Comorbidities and Hospital Activity: Single Centre Experience from 2000 to 2009. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
184
|
Lim H, John B, Lau D, Dimitri H, Sanders P. Twin Left Atrial Flutters Using a Common Scar Isthmus Presenting with Tachycardia of Alternating Cycle Length. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
185
|
Cheng Y, Yam C, Wong C, Brooks A, Lau D, Leong D, Shipp N, Alasady M, Lim H, Abed H, Sanders P. Age and Gender-Specific Trends for Asymmetrical Septal Hypertrophy in a Single Centre Over 15 Years (1994–2009). Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
186
|
Alasady M, Abhayaratna W, Leong D, Lim H, Barlow D, Roberts-Thomson K, Chew D, Sanders P. Left Atrial Structural Remodeling as a Consequence of Myocardial Infarction: Relationship to Adverse Cardiovascular Outcome. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
187
|
Lim H, Wilson L, Lau D, Kyriacou N, Alasady M, Leong D, Abed H, Dimitri H, Laborderie J, Shipp N, Kuklik P, Willoughby S, Sanders P. Unusual Left Atrial Thrombus Site Undetected by Trans-Oesophageal Echocardiography. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
188
|
Wilson L, Wong C, Kyriacou N, Kuklik P, Brooks A, Lau D, Alasady M, Lim H, Abed H, Dimitri H, Young G, Sanders P. Left Atrial and Pulmonary Venous Anatomy: Variability in Patients Undergoing Atrial Fibrillation Ablation. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.917] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
189
|
Lim H, Willoughby S, Gan C, Schultz C, Lau D, Leong D, Alasady M, Dimitri H, Brooks A, Wilson L, Roberts-Thomson K, Worthley M, Young G, Sanders P. Left Atrial Thrombogenesis Due to Atrial Fibrillation: Is it Rate or Rhythm? Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
190
|
Wong C, Cheng Y, Sun M, Lau D, Brooks A, Leong D, Shipp N, Alasady M, Lim H, Abed H, Roberts-Thomson K, Sanders P. Atrial Fibrillation Hospitalisations in Australia: Increasing Nation-Wide Trends (1998–2008). Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
191
|
Alasady M, Wong D, Leong D, Abhayaratna W, Roberts-Thomson K, Barlow D, Lim H, Brooks A, Worthley S, Worthley M, Sanders P. Using Intracoronary Electrocardiography in Diagnosing Atrial Ischemia During Acute Myocardial Infarction. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.938] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
192
|
Tay A, Walker B, Lim H, Subbiah R, Kuchar D, Thorburn C. Cardiac Device and Lead Displacement Secondary to Significant Weight Loss in the Obese Patient. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
193
|
Lau D, Mackenzie L, Kelly D, Shipp N, Drury K, Lim H, Chia N, Kuklik P, Zhang Y, Dimitri H, Lobb B, Brooks A, Saint D, Brown L, Sanders P. High Density Multiple Electrode Characterization of the Substrate for Atrial Arrhythmias in Spontaneously Hypertensive Rats. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
194
|
Dimitri H, Ng M, Brooks A, Antic N, Thornton A, Abed H, Alasady M, Lau D, Lim H, McEvoy D, Antic R, Sanders P. The Severity of Obstructive Sleep Apnoea Determines the Persistence and Symptoms of Atrial Fibrillation. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
195
|
Schultz C, Willoughby S, Lim H, Alasady M, Dimitri H, Lau D, Laborderie J, Roberts-Thomson K, Young G, Sanders P. Characterizations of Platelet Activity, Endothelial Function and Inflammation in Patients with Supraventricular Tachycardia. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
196
|
Wong C, Sun M, Brooks A, Lau D, Leong D, Shipp N, Alasady M, Lim H, Abed H, Dang J, Roberts-Thomson K, Sanders P. Age and Gender-Specific Trends for ICD Implantations in Australia: 2000–2008. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
197
|
Marcoux J, Sohn N, McNair E, Rosin M, Smith G, Lim H, Mycyk T, Meng Q. Outcomes comparison of 5 coated cardiopulmonary bypass circuits versus an uncoated control group of patients undergoing cardiac surgery. Perfusion 2009; 24:307-15. [DOI: 10.1177/0267659109352114] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Attenuated inflammatory response and decreased platelet activation have been claimed repeatedly when biocompatible circuits are used for cardiopulmonary bypass. We evaluated five Health Canada approved biocompatible circuit coatings (BCC) against an un-coated control group to determine their effectiveness in improving post-operative outcomes. Patients were assigned to the Control group or one of the 5 coated circuit groups: 40 Control; 33 Trillium; 32 Phisio; 34 Bioline; 33 X; and 11 GBS. Measured outcomes included: ventilator time; ICU time; post-operative chest tube drainage and transfusion volume; high sensitivity C-reactive protein (hsCRP); tau protein; and pre- and 72-hour post-operative anti-saccadic eye movement test comparisons. Results: 183 patients were enlisted into the study. One arm of the study (GBS) was abandoned after 11 patients on account of inconsistent pressure excursions within the oxygenator and the excessive consumption of platelets necessitating transfusion. Patients in the X-coated group had significantly longer ventilator and intensive care unit (ICU) time compared to the three remaining coated circuit study groups. Though not significant, patients in the X group also demonstrated the highest post-operative chest tube losses, the most platelet transfusions, the highest tau protein levels and the lowest post-operative anti-saccadic eye movement test (ASEMT) results compared to the three remaining coated groups. The patients in the Trillium, Bioline and Phisio groups showed an improvement in ventilator and ICU time relative to the Control group. The diabetic patients in the Trillium, Bioline and Phisio groups showed an improvement in bleeding relative to the diabetic patients in the Control group. Conclusion: We compared all 5 coated circuits approved for clinical use in Canada against an uncoated control circuit. Three of the 5 coated circuits (Trillium, Phisio and Bioline BCC) were found to improve ventilator and ICU time compared to Control. Further studies are indicated to validate these results and their impact upon approval criteria, purchasing choices and safe clinical practice, especially as applied to higher risk diabetic patients.
Collapse
|
198
|
Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Alexander J, Al-Jamel A, Aoki K, Aphecetche L, Armendariz R, Aronson SH, Averbeck R, Awes TC, Azmoun B, Babintsev V, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Bathe S, Batsouli S, Baublis V, Bauer F, Bazilevsky A, Belikov S, Bennett R, Berdnikov Y, Bjorndal MT, Boissevain JG, Borel H, Boyle K, Brooks ML, Brown DS, Bucher D, Buesching H, Bumazhnov V, Bunce G, Burward-Hoy JM, Butsyk S, Campbell S, Chai JS, Chernichenko S, Chiba J, Chi CY, Chiu M, Choi IJ, Chujo T, Cianciolo V, Cleven CR, Cobigo Y, Cole BA, Comets MP, Constantin P, Csanád M, Csörgo T, Dahms T, Das K, David G, Delagrange H, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Drachenberg JL, Drapier O, Drees A, Dubey AK, Durum A, Dzhordzhadze V, Efremenko YV, Egdemir J, Enokizono A, En'yo H, Espagnon B, Esumi S, Fields DE, Fleuret F, Fokin SL, Forestier B, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fukao Y, Fung SY, Gadrat S, Gastineau F, Germain M, Glenn A, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HA, Hachiya T, Hadj Henni A, Haggerty JS, Hagiwara MN, Hamagaki H, Harada H, Hartouni EP, Haruna K, Harvey M, Haslum E, Hasuko K, Hayano R, Heffner M, Hemmick TK, Heuser JM, He X, Hiejima H, Hill JC, Hobbs R, Holmes M, Holzmann W, Homma K, Hong B, Horaguchi T, Hur MG, Ichihara T, Imai K, Inaba M, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Jacak BV, Jia J, Jin J, Jinnouchi O, Johnson BM, Joo KS, Jouan D, Kajihara F, Kametani S, Kamihara N, Kaneta M, Kang JH, Kawagishi T, Kazantsev AV, Kelly S, Khanzadeev A, Kim DJ, Kim E, Kim YS, Kinney E, Kiss A, Kistenev E, Kiyomichi A, Klein-Boesing C, Kochenda L, Kochetkov V, Komkov B, Konno M, Kotchetkov D, Kozlov A, Kroon PJ, Kunde GJ, Kurihara N, Kurita K, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lajoie JG, Lebedev A, Le Bornec Y, Leckey S, Lee DM, Lee MK, Leitch MJ, Leite MAL, Lim H, Litvinenko A, Liu MX, Li XH, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Masui H, Matathias F, McCain MC, McGaughey PL, Miake Y, Miller TE, Milov A, Mioduszewski S, Mishra GC, Mitchell JT, Morrison DP, Moss JM, Moukhanova TV, Mukhopadhyay D, Murata J, Nagamiya S, Nagata Y, Nagle JL, Naglis M, Nakamura T, Newby J, Nguyen M, Norman BE, Nouicer R, Nyanin AS, Nystrand J, O'Brien E, Ogilvie CA, Ohnishi H, Ojha ID, Okada H, Okada K, Omiwade OO, Oskarsson A, Otterlund I, Ozawa K, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park J, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Pisani RP, Purschke ML, Purwar AK, Qu H, Rak J, Ravinovich I, Read KF, Reuter M, Reygers K, Riabov V, Riabov Y, Roche G, Romana A, Rosati M, Rosendahl SSE, Rosnet P, Rukoyatkin P, Rykov VL, Ryu SS, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Samsonov V, Sato HD, Sato S, Sawada S, Semenov V, Seto R, Sharma D, Shea TK, Shein I, Shibata TA, Shigaki K, Shimomura M, Shohjoh T, Shoji K, Sickles A, Silva CL, Silvermyr D, Sim KS, Singh CP, Singh V, Skutnik S, Smith WC, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sullivan JP, Sziklai J, Tabaru T, Takagi S, Takagui EM, Taketani A, Tanaka KH, Tanaka Y, Tanida K, Tannenbaum MJ, Taranenko A, Tarján P, Thomas TL, Togawa M, Tojo J, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Tuli SK, Tydesjö H, Tyurin N, Vale C, Valle H, van Hecke HW, Velkovska J, Vértesi R, Vinogradov AA, Vznuzdaev E, Wagner M, Wang XR, Watanabe Y, Wessels J, White SN, Willis N, Winter D, Woody CL, Wysocki M, Xie W, Yanovich A, Yokkaichi S, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zimányi J, Zolin L. Charged Kaon interferometric probes of space-time evolution in Au+Au collisions at sqrt[S(NN)]=200 GeV. PHYSICAL REVIEW LETTERS 2009; 103:142301. [PMID: 19905563 DOI: 10.1103/physrevlett.103.142301] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/28/2009] [Indexed: 05/28/2023]
Abstract
Bose-Einstein correlations of charged kaons are used to probe Au+Au collisions at sqrt[S(NN)]=200 GeV and are compared to charged pion probes, which have a larger hadronic scattering cross section. Three-dimensional Gaussian source radii are extracted, along with a one-dimensional kaon emission source function. The centrality dependences of the three Gaussian radii are well described by a single linear function of N(part)1/3 with a zero intercept. Imaging analysis shows a deviation from a Gaussian tail at r greater than or approximately equal to 10 fm, although the bulk emission at lower radius is well described by a Gaussian. The presence of a non-Gaussian tail in the kaon source reaffirms that the particle emission region in a heavy-ion collision is extended, and that similar measurements with pions are not solely due to the decay of long-lived resonances.
Collapse
|
199
|
Rhee H, Horstemeyer M, Hwang Y, Lim H, El Kadiri H, Trim W. A study on the structure and mechanical behavior of the Terrapene carolina carapace: A pathway to design bio-inspired synthetic composites. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2009. [DOI: 10.1016/j.msec.2009.06.002] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
200
|
Kim S, Lee J, Park S, Park Y, Lim H, Kang W, Choi S, Choi D, Lim D, Park J. 6592 Prognostic model to predict outcomes in pancreatic adenocarcimoma patients who received surgical resection with curative intent. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71313-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|